Alternative Medicine Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alternative Medicine Times.

Press releases published on September 8, 2026

Sep. 8, 2026

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

Indeterminate GlobeNewswire

Sep. 8, 2026

Rani Therapeutics to Participate in Upcoming September Conferences

Indeterminate GlobeNewswire

Sep. 8, 2026

AirNexis Therapeutics Announces that AN01, a Dual PDE3/4 Inhibitor Dry Powder Inhaler (DPI) Met its Primary Endpoint in a Phase 2b COPD Study (HSK39004-T1-202) Conducted in China by AirNexis' partner Haisco Pharmaceutical Group

Indeterminate GlobeNewswire

Sep. 8, 2026

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

Indeterminate GlobeNewswire

Sep. 8, 2026

Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET

Indeterminate GlobeNewswire

Sep. 8, 2026

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Indeterminate GlobeNewswire

Sep. 8, 2026

Amwell Receives Letter of Intent from Department of Veterans Affairs to Help Power its Digital Health Infrastructure

Indeterminate GlobeNewswire

Sep. 8, 2026

MIMEDX to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 8, 2026

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Indeterminate GlobeNewswire

Sep. 8, 2026

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

Indeterminate GlobeNewswire

Sep. 8, 2026

Health Catalyst Appoints Simeon Kohl as Chief Executive Officer and President

Indeterminate GlobeNewswire

Sep. 8, 2026

R1 Makes Fast Company’s Eighth Annual List of the Best Workplaces for Innovators in Biotech, Healthcare and Life Sciences

Indeterminate GlobeNewswire

Sep. 8, 2026

Windward Bio announces positive Phase 2 results of WIN378 in asthma demonstrating significant improvements in lung function and airway inflammation with twice-yearly dosing, and initiates Phase 3

Indeterminate GlobeNewswire

Sep. 8, 2026

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

Indeterminate GlobeNewswire

Sep. 8, 2026

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results

Indeterminate GlobeNewswire

Sep. 8, 2026

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

Indeterminate GlobeNewswire

Sep. 8, 2026

CervoMed to Participate in September Investor Conferences

Indeterminate GlobeNewswire

Sep. 8, 2026

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Indeterminate GlobeNewswire

Sep. 8, 2026

BioVie Announces Update to Parkinson’s Phase 3 Development Program

Indeterminate GlobeNewswire

Sep. 8, 2026

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Indeterminate GlobeNewswire